Abstract:OBJECTIVE To evaluate the dosing regimens of levofloxacin. METHODS The drug concentrations in serum and urine were assayed by HPLC method and the pharmacokinetic parameters were calculated after intravenous infusion of a single dose of 200 mg, 300 mg and 500 mg levofloxacin to healthy volunteers. The in vitro activity MIC of levofloxacin against 823 clinical isolates were determined and compared with other antimicrobial agents. Based on the above results, the PK/PD parameters C(max)/MIC and AUC/MIC were calculated and the dosing regimens of levofloxacin were proposed for infections caused by different pathogens. RESULTS The results of clinical pharmacokinetic study showed that the C(max) of levofloxacin was 3.4 mg/L +/- 0.8 mg/L, 4.8 mg/L +/- 1.4 mg/L and 7.6 mg/L +/- 1.1 mg/L respectively, AUC(0-infinity) was 14.4 mg.h/L +/- 2.5 mg.h/L, 21.9 mg.h/L +/- 4.5 mg.h/L and 38.3 mg.h/L +/- 4.9 mg.h/L respectively, T(1)/2 beta was 6.2 h +/- 0.4 h, 6.4 h +/- 0.9 h and 6.5 h +/- 0.6 h respectively, and 69% +/- 5%, 69% +/- 6%, and 65% +/- 4% of the doses were excreted in urine within 24 h after intravenous infusion of a single dose of levofloxacin 200 mg, 300 mg and 500 mg. The in vitro pharmacodynamic study showed that levofloxacin was highly active against Hemolytic streptococcus and Moraxella catarrhalis. It was active against Streptococcus pneumoniae (including penicillin nonsusceptible strains), Hemophilus influenzae, methicillin-sensitive Staphylococcus aureus (MSSA), Klebsiella pneumoniae and Stenotrophomonas maltophilia. Levofloxacin also had good activity against Pseudomonas aeruginosa and K.pneumoniae. However, most of isolates of enterococcal spp. were resistant to levofloxacin. Above 50% of Escherichia coli isolates were resistant to levofloxacin. Based on the results of PK/PD parameters, the adequate dosing regimens of levofloxacin should be once daily 200 mg once daily of levofloxacin was expected to be effective for the treatment of infections caused by M. catarrhalis. The regimen of 300 mg once daily could be effective for the treatment of infections caused by Hemolytic streptococcus. 500 mg once daily of levofloxacin was expected to be effective for the treatment of respiratory tract infections caused by S. pneumoniae or H. influenzae. For treatment of respiratory tract infections and urinary tract infections caused by levofloxacin-susceptible organisms including K. pneumoniae, E. coli, P. aeruginosa, and S.maltophilia, 500 mg once daily of levofloxacin was needed to obtain good clinical efficacy. But PK/PD parameters predicted that 500 mg daily of levofloxacin was not effective for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and Enterococci. CONCLUSION The proposed dosing regimens of levofloxacin based on PK/PD concepts are expected to provide good efficacy in clinical practice.

Clinical Study on High Dosage Levofloxacin Veno-Preparation for the Treatment of Respiratory Tract Infections

Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China

A randomized multicenter clinical study of injectable levofloxacin in the treatment of acute bacterial infections

Meta-analysis of High-dose and Routine-dose of Levofloxacin in the Treatment of Respiratory Tract Infection

Clinical evaluation of pazufloxacin and levofloxacin in the treatment of bacterial infections

Population Pharmacokinetics of Oral Levofloxacin 500mg Once-Daily Dosage in Community-Acquired Lower Respiratory Tract Infections: Results of a Prospective Multicenter Study in China

Permeability and Concentration of Levofloxacin in Epithelial Lining Fluid in Patients with Lower Respiratory Tract Infections

A retrospective study of the efficacy and safety of levofloxacin in children with severe infection

A Randomized Controlled Clinical Study on a New Quinolone,gatifloxacin, in the Treatment of Respiratory Tract Infections

A randomized, open, multicenter clinical study on the short course of intravenous infusion of 750 mg of levofloxacin and the sequential standard course of intravenous infusion/oral administration of 500 mg of levofloxacin for treatment of community-acquired pneumonia

A clinical randomized controlled trial of pazufloxacin injection in treatment of bacterial infection in 111 patients

Pharmacokinetics of single 500-milligram doses of intravenous levofloxacin in middle-age healthy volunteers

Randomized Controlled Clinical Trial of Moxifloxacin Versus Levofloxacin Injection in the Treatment of Community Acquired Pneumonia

An Open-Label, Uncontrolled, Multicenter Study to Evaluate the Efficacy and Safety of Oral Levofloxacin 500 Mg Once Daily in Patients with Lower Respiratory Tract Infections or Urinary Tract Infections

Intravenous Moxifloxacin in Routine Hospital Treatment of Respiratory Tract Infections in China: Results of a Multicenter, Noninterventional Study.

[Efficacy and Safety of Cefditoren Pivoxil in Treatment of Respiratory Infections, a Clinical Study].

A Multi-Center, Randomized, Controlled, Double Blind and Double Dummy Clinical Trial of Antofloxacin Hydrochloride Tablet Versus Levofloxacin Tablet for the Treatment of Acute Bacterial Infections

[Study of Pharmacokinetics/pharmacodynamics of Levofloxacin].

Multi-center Clinical Studies on Pazufloxacin Sodium Chloride Injection in Treatment for Acute Bacterial Infections

[Adverse Drug Reaction and Rational Use of Levofloxacin: a Prospective Study].

A Phase Ii Study of Antofloxacin Hydrochloride, A Novel Fluoroquinolone, for the Treatment of Acute Bacterial Infections